FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:712-714 September 4, 1997 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Apsner, R. Related Article by Forni, L.G.

To the Editor: The review article by Forni and Hilton on continuous hemofiltration for the treatment of acute renal failure (May 1 issue)¹ suggests that this therapy should be used more widely. That may prove to be the case. However, as the article notes, there is little support for this approach in published reports. None of the references cited demonstrated in a randomized, controlled trial that this therapy reduces morbidity or mortality. Moreover, a preliminary report of a multicenter randomized trial comparing continuous therapy with intermittent dialysis found that continuous therapy had no benefit.²

There are important considerations of cost. . . . [Full Text of this Article]

References

Related Letters:

More on Anticoagulation for Continuous Hemofiltration
Apsner R., Druml W., Hsu C.-y., Palsson R., Niles J. L.
Extract | Full Text  
N Engl J Med 1998; 338:131-132, Jan 8, 1998. Correspondence

This article has been cited by other articles:

• Ramachandran, M., Ward, K., Brown, R. R., Munns, C. F., Cowell, C. T., Little, D. G. (2007). Intravenous Bisphosphonate Therapy for Traumatic Osteonecrosis of the Femoral Head in Adolescents. JBJS 89: 1727-1734 [Abstract] [Full Text]  
• Agarwala, S., Jain, D., Joshi, V. R., Sule, A. (2005). Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44: 352-359 [Abstract] [Full Text]